多发性硬化患者使用精神类药物与骨折风险的真实世界研究
这项全球回顾性队列研究基于TriNetX网络,经1:1倾向评分匹配纳入117,534例成人多发性硬化患者,随访5年。精神类药物使用者全骨折风险(HR 2.41)和多发性硬化复发风险(HR 3.63)显著升高,死亡率无显著差异;阿片类镇痛药为骨折高危因素(HR 3.83)。
要点
- 精神类药物使用与多发性硬化患者全骨折风险升高相关(HR 2.41)。
- 阿片类镇痛药是骨折风险的主要贡献因素(HR 3.83),非阿片类镇痛药无显著关联。
- 精神类药物使用与多发性硬化复发风险升高相关(HR 3.63),死亡率无显著差异。
核心结论
- 多发性硬化患者使用精神类药物与骨折和复发风险升高相关,主要由阿片类镇痛药驱动,对死亡率无显著影响。
研究设计与样本
- 全球回顾性队列研究,使用TriNetX研究网络,纳入成人多发性硬化患者,按1:1倾向评分匹配分为精神类药物组和对照组。
- 匹配后共纳入117,534例患者(每组58,777例),随访5年,评估全骨折、多发性硬化复发和死亡率。
主要发现
- 精神类药物使用者全骨折风险显著升高(HR 2.41;95%CI 2.22-2.63;NNH 49)。
- 精神类药物使用者多发性硬化复发风险显著升高(HR 3.63;95%CI 3.51-3.75;NNH 6)。
- 两组死亡率无显著差异。
- 交互检验显示镇痛药使用是骨折风险的主要贡献因素。
- 亚组分析显示阿片类使用者骨折风险更高(HR 3.83;95%CI 3.45-4.25;NNH 24),非阿片类镇痛药与总体骨折风险无显著关联。
临床怎么用
- 对多发性硬化患者应优先考虑骨骼安全的疼痛管理策略并重视跌倒预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In this global real-world study, psychotropic medications, particularly analgesics, were associated with increased risks of fractures (HR, 2.41; P < 0.001) and disease relapse (HR, 3.63; P < 0.001) in patients with multiple sclerosis. Interaction analyses further indicated a higher fracture risk among opioid users (HR, 3.83; P < 0.001). PURPOSE: Patients with multiple sclerosis (MS) frequently require psychotropic medications, yet their effects on fracture risk and disease activity remain unclear. This study evaluated the risks of fractures, MS relapse, and mortality associated with psychotropic medication use in patients with MS. METHODS: We conducted a global, retrospective cohort study using the TriNetX Research Network. Adult patients with MS were categorized into a psychotropics group and a control group. Propensity score matching in a 1:1 ratio was performed to balance baseline covariates. Primary outcomes included risks of all fractures (hip, vertebral, and extremity), MS relapse, and mortality assessed over a 5-year follow-up. Interaction analyses were performed to determine the differential effects of medication classes. RESULTS: After matching, 117,534 patients (58,777 per group) were included. At the 5-year follow-up, the psychotropic users exhibited significantly higher risks of all fractures (HR, 2.41; 95% CI 2.22-2.63; NNH, 49) and MS relapse (HR, 3.63; 95% CI 3.51-3.75; NNH, 6). No significant difference was observed in mortality. Interaction testing revealed that analgesic use was the primary contributor to fracture risk. Subgroup analysis further identified opioids as the high-risk agent (HR, 3.83; 95% CI 3.45-4.25; NNH, 24), whereas non-opioid analgesics showed no significant association with overall fracture risk. CONCLUSIONS: Psychotropic medication use was associated with increased fracture and relapse risk in multiple sclerosis, driven primarily by opioid analgesics, without an effect on mortality. Bone-conscious pain management and fall prevention should be prioritized.
引用
- Wang PC, Chen KE, Lin HA, et al. Psychotropic medication use and bone fracture risk among patients with multiple sclerosis: a real-world study. Osteoporos Int. 2026. PMID: 41697311. doi:10.1007/s00198-026-07887-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。